Association between Quality of Life and Visual Acuity in a Randomized Clinical Trial of Patients with Uveitis Taking Antimetabolites.
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial
health related quality of life
quality of life
vision related quality of life
visual acuity
Journal
Ocular immunology and inflammation
ISSN: 1744-5078
Titre abrégé: Ocul Immunol Inflamm
Pays: England
ID NLM: 9312169
Informations de publication
Date de publication:
07 Feb 2023
07 Feb 2023
Historique:
pmc-release:
07
08
2024
entrez:
7
2
2023
pubmed:
8
2
2023
medline:
8
2
2023
Statut:
aheadofprint
Résumé
To evaluate how changes in visual acuity are associated with changes in quality of life (QoL) among patients with non-infectious uveitis taking antimetabolites. This secondary analysis of the multicenter First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial involves 216 participants randomized to methotrexate or mycophenolate mofetil. Vision-related (NEI-VFQ and IND-VFQ) and health-related (PCS and MCS SF-36v2) QoL and visual acuity were measured at baseline and 6-month primary endpoint. Visual acuity was significantly associated and correlated with all QoL measures (Spearman correlation coefficients = 0.5, 0.5, 0.3, and 0.4 for NEI-VFQ, IND-VFQ, SF-36v2 MCS and PCS, respectively). All observed changes in QoL met or exceeded the minimal clinically important difference definition on each scale. Treatment group was not significantly associated with any QoL measure. By adding insight beyond visual acuity, QoL provides a more comprehensive picture of the patient experience during uveitis treatment.
Identifiants
pubmed: 36749914
doi: 10.1080/09273948.2023.2169714
pmc: PMC10404633
mid: NIHMS1871984
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-9Subventions
Organisme : NEI NIH HHS
ID : U10 EY021125
Pays : United States
Références
Am J Ophthalmol. 2005 Sep;140(3):509-16
pubmed: 16196117
Invest Ophthalmol Vis Sci. 2012 Mar 09;53(3):1169-76
pubmed: 22247489
Gerontol Geriatr Med. 2018 Sep 20;4:2333721418801601
pubmed: 30263908
Indian J Endocrinol Metab. 2021 Sep-Oct;25(5):365-380
pubmed: 35300441
Ophthalmology. 2021 Sep;128(9):1337-1345
pubmed: 33675850
Ophthalmology. 2020 Dec;127(12):1710-1718
pubmed: 32717341
Biologics. 2014 Feb 15;8:67-81
pubmed: 24600203
PLoS One. 2012;7(8):e44268
pubmed: 22952945
Br J Ophthalmol. 2005 May;89(5):621-7
pubmed: 15834097
Acta Ophthalmol. 2016 Aug;94(5):e331-9
pubmed: 26932535
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Am J Ophthalmol. 2004 Jul;138(1):91-108
pubmed: 15234287
Health Qual Life Outcomes. 2003 Apr 11;1:4
pubmed: 12737635
JAMA Ophthalmol. 2017 Jun 1;135(6):511-518
pubmed: 28426849
Am J Ophthalmol. 2000 Oct;130(4):492-513
pubmed: 11024423
Indian J Community Med. 2013 Jan;38(1):22-6
pubmed: 23559699
JAMA. 1989 Aug 18;262(7):925-30
pubmed: 2754793
BMJ. 1992 Jul 18;305(6846):160-4
pubmed: 1285753
Arch Ophthalmol. 2001 Jun;119(6):841-9
pubmed: 11405835
Ophthalmology. 2015 Oct;122(10):1976-86
pubmed: 26298718
Am J Ophthalmol. 2017 Jul;179:10-17
pubmed: 28414043
Ocul Immunol Inflamm. 2010 Aug;18(4):297-304
pubmed: 20482406
Arch Ophthalmol. 2001 Jul;119(7):1050-8
pubmed: 11448327
Ophthalmology. 2003 Jun;110(6):1076-81
pubmed: 12799229
Control Clin Trials. 1999 Dec;20(6):573-600
pubmed: 10588299
Z Gerontol Geriatr. 2010 Aug;43(4):259-63
pubmed: 19806290
Ocul Immunol Inflamm. 2012 Aug;20(4):262-5
pubmed: 22568885
Middle East Afr J Ophthalmol. 2014 Jul-Sep;21(3):225-31
pubmed: 25100906
Br J Ophthalmol. 2007 Feb;91(2):154-6
pubmed: 16973657
Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3629-35
pubmed: 19255158
Indian J Ophthalmol. 2008 Jul-Aug;56(4):307-12
pubmed: 18579990
Ophthalmologica. 2004 Jul-Aug;218(4):223-36
pubmed: 15258410
Invest Ophthalmol Vis Sci. 2011 Aug 01;52(9):6081-8
pubmed: 21693607
Clin Exp Hepatol. 2018 Dec;4(4):232-239
pubmed: 30603670
JAMA. 2019 Sep 10;322(10):936-945
pubmed: 31503307
Surv Ophthalmol. 2001 May-Jun;45(6):531-48
pubmed: 11425359